Lipid Imaging Tool for Drug Development in Metabolic Diseases to be Presented at Bio-Tech Israel 2005.TEL AVIV Tel Aviv (tĕl əvēv`), city (1994 pop. 355,200), W central Israel, on the Mediterranean Sea. Oficially named Tel Aviv–Jaffa, it is Israel's commercial, financial, communications, and cultural center and the core of its largest , Israel -- QuantomiX Ltd. will present its high-resolution lipid imaging technology at Bio-Tech Israel 2005 on May 24, accompanied by high expectations from industry leaders. This technology permits high resolution imaging, analysis, and quantification of lipid bodies in cells and tissues (liver, muscle, adipose tissue adipose tissue (ăd`əpōs'): see connective tissue. adipose tissue or fatty tissue Connective tissue consisting mainly of fat cells, specialized to synthesize and contain large globules of fat, within a etc.) - a capability that can serve as an early indication for the onset of metabolic disorders. Recent research has revealed that lipid imaging using QuantomiX WETSEM(TM) technology may hold the key to drug evaluation for metabolic diseases metabolic disease, n a disorder that causes dysfunction of the metabolic action of the body, resulting in loss of control of homeostasis. paraneoplastic syndrome . Lipid imaging under high resolution is crucial for diagnostics and drug monitoring of insulin resistance Insulin Resistance Definition Insulin resistance is not a disease as such but rather a state or condition in which a person's body tissues have a lowered level of response to insulin, a hormone secreted by the pancreas that helps to regulate the level , a key component in understanding metabolic syndrome metabolic syndrome n. See syndrome X. Metabolic syndrome A group of risk factors for heart disease, diabetes, and stroke. . The ability to view the process of fat accumulation in tissues with WETSEM(TM), provides an early indication on the effectiveness of drugs in pre-clinical and clinical trials. With the importance of metabolic syndrome in the developed world, this ability is crucial for modern drug development. Bio-Tech Israel 2005 - The Israel Biomedical Technologies Conference and Exhibition, scheduled to take place on May 24-26, 2005 in Tel Aviv, Israel, is an annual event which brings together the players in the biotech field worldwide. The 2005 conference will focus on four disease areas, one of which is metabolic disorders. "This focus has pushed QuantomiX to present its exciting technology at Bio-Tech," explains Ory Zik, the company's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "The QuantomiX technology is highly useful in metabolic syndrome research, and can become a stepping stone to better understanding of this range of disorders," he clarifies. Barbara Corkey, Ph.D., Professor of Medicine and Biochemistry and Director of the Obesity Research Center at Boston Medical Center Boston Medical Center (BMC) is a non-profit 581-bed medical center in Boston, Massachusetts. It was created by the formal merger of Boston City Hospital (BCH) and Boston University Medical Center Hospital (BUMCH). , Boston University Boston University, at Boston, Mass.; coeducational; founded 1839, chartered 1869, first baccalaureate granted 1871. It is composed of 16 schools and colleges. , and a member of QuantomiX's advisory board will be attending the Bio-Tech conference. "QuantomiX technology promises to be an important aid in lipid accumulation research as part of the study of obesity," she declares. QuantomiX technology, the only comprehensive solution for lipid imaging and quantification, is expected to open new vistas in drug development for metabolic syndrome and other hitherto unexplored avenues of research. About QuantomiX QuantomiX develops and markets breakthrough solutions based on its proprietary WETSEM(TM) technology. QuantomiX innovative technology which allows high resolution imaging of wet samples, opens new opportunities for application-specific tools to improve drug discovery, and advances treatment and diagnostic solutions for the medical and pharmaceutical markets. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion